released November 14, 2020
[Official website - 【www.mycashbackforex.com】] - Stable and profitable EA, online boutique mentor, various indicator systems, you can find customer service to obtain a professional foreign exchange expert trading indicator system after registration, and a fast and stable foreign exchange cross-platform ordering system is waiting for you !! Sign up ~->>https://www.exness-168.com/a/uiona5hf The main dealer in the foreign exchange market and represents the highest standards in the world's foreign exchange trading industry today. As the FSCM futures trading committee supervision, we always adhere to the The strict financial reporting and capital adequacy standards promoted by the association. As one of the most prestigious companies in this industry, we provide individual investors, hedge funds and corporate clients with real-time updated quote information 24 hours a day , Represents the most advanced level of trading software, fast and fair transaction implementation functions and comprehensive customer service. Our advantages are: Commission-free transactions, no commission fees Minimal spreads, the main currency is 0.4 Floating spreads from Margin trading, leverage ratio: 100: 1, 200: 1, 300: 1, 400: 1, 500: 1, 1000: 1 you can choose flexible contract size, 1K, 5K , 10K, 5 0K, 100K choose as you please Extremely low account opening standards, as low as US $ 1 Advanced global trading platform Free forex trading news Free forex trading charts Full hedge trading method, trail Stop loss function 24 hours Chinese online customer service Advanced risk management tools Click the link below to open an account now!
A staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd, in Beijing on March 16, 2020. [Photo/Xinhua]
LONDON — A Chinese COVID-19 vaccine candidate based on the inactivated whole SARS-CoV-2 virus is safe and elicits an antibody response, according to the findings from a small early-phase randomised clinical trial published Thursday in The Lancet Infectious Diseases journal.
The latest study included participants aged between 18 and 80 years, and found that antibody responses were induced in all recipients. Participants aged 60 and older were slower to respond, taking 42 days before antibodies were detected in all recipients compared with 28 days for participants aged 18-59.
The trial was not designed to assess efficacy of the vaccine, so it is not possible to say whether the antibody responses induced by the vaccine, called BBIBP-CorV, are sufficient to protect people from SARS-CoV-2 infection.
The authors also noted that interpretation of the results of this study is limited by the short duration of follow-up.
According to The Lancet, there are currently 42 vaccines for COVID-19 in clinical trials. Vaccine candidates in clinical trials vary in type and include DNA plasmid vaccines, inactivated virus vaccines, adenovirus-vectored vaccines, RNA vaccines, protein subunit vaccines and virus-like particle vaccines. Some of these have already proved safe and able to elicit immune responses in early phase clinical trials.
"Our findings indicate that a booster shot is necessary to achieve the greatest antibody responses against SARS-CoV-2 and could be important for protection. This provides useful information for a phase 3 trial," said Yang Xiaoming, one of the authors of the study and a professor from the Beijing Institute of Biological Products.